330 related articles for article (PubMed ID: 26234524)
1. Pharmacological stimulation of serotonin 5-HT1B receptors enhances increases in plasma active glucagon-like peptide-1 levels induced by dipeptidyl peptidase-4 inhibition independently of feeding in mice.
Nonogaki K; Kaji T
Diabetes Metab; 2015 Nov; 41(5):425-8. PubMed ID: 26234524
[TBL] [Abstract][Full Text] [Related]
2. Mosapride, a selective serotonin 5-HT4 receptor agonist, and alogliptin, a selective dipeptidyl peptidase-4 inhibitor, exert synergic effects on plasma active GLP-1 levels and glucose tolerance in mice.
Nonogaki K; Kaji T
Diabetes Res Clin Pract; 2015 Dec; 110(3):e18-21. PubMed ID: 26497774
[TBL] [Abstract][Full Text] [Related]
3. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
[TBL] [Abstract][Full Text] [Related]
4. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100
[TBL] [Abstract][Full Text] [Related]
5. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
Br J Pharmacol; 2009 Jun; 157(3):415-26. PubMed ID: 19371350
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
[TBL] [Abstract][Full Text] [Related]
7. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
Moritoh Y; Takeuchi K; Hazama M
J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
[TBL] [Abstract][Full Text] [Related]
8. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.
Cho JM; Jang HW; Cheon H; Jeong YT; Kim DH; Lim YM; Choi SH; Yang EK; Shin CY; Son MH; Kim SH; Kim HJ; Lee MS
Diabetes Res Clin Pract; 2011 Jan; 91(1):72-9. PubMed ID: 21093089
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
[TBL] [Abstract][Full Text] [Related]
10. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
Asakawa T; Moritoh Y; Kataoka O; Suzuki N; Takeuchi K; Odaka H
Life Sci; 2009 Jul; 85(3-4):122-6. PubMed ID: 19427871
[TBL] [Abstract][Full Text] [Related]
11. Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice.
Moritoh Y; Takeuchi K; Hazama M
Diabetes Obes Metab; 2010 Mar; 12(3):224-33. PubMed ID: 20151999
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet.
Nakaya K; Kubota N; Takamoto I; Kubota T; Katsuyama H; Sato H; Tokuyama K; Hashimoto S; Goto M; Jomori T; Ueki K; Kadowaki T
Metabolism; 2013 Jul; 62(7):939-51. PubMed ID: 23790528
[TBL] [Abstract][Full Text] [Related]
13. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.
Kim TE; Lim KS; Park MK; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2012 Sep; 34(9):1986-98. PubMed ID: 22943970
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibition in diabetic rats leads to activation of the transcription factor CREB in β-cells.
Pugazhenthi S; Qin L; Bouchard R
Eur J Pharmacol; 2015 May; 755():42-9. PubMed ID: 25720341
[TBL] [Abstract][Full Text] [Related]
17. Oral Administration of Collagen Hydrolysates Improves Glucose Tolerance in Normal Mice Through GLP-1-Dependent and GLP-1-Independent Mechanisms.
Iba Y; Yokoi K; Eitoku I; Goto M; Koizumi S; Sugihara F; Oyama H; Yoshimoto T
J Med Food; 2016 Sep; 19(9):836-43. PubMed ID: 27540823
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen deficiency is associated with improved glucose tolerance, and lower DPP-4 activity.
Kanno Y; Sakai A; Miyashita M; Tsuchida K; Matsuo O
Diabetes Res Clin Pract; 2016 Oct; 120():190-3. PubMed ID: 27592166
[TBL] [Abstract][Full Text] [Related]
19. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
[TBL] [Abstract][Full Text] [Related]
20. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.
Ahrén B; Holst JJ; Mårtensson H; Balkan B
Eur J Pharmacol; 2000 Sep; 404(1-2):239-45. PubMed ID: 10980284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
